An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Name: An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Published: 2016
License: Public Domain

Millennium Pharmaceuticals, Inc. · 2016

ClinicalTrials.gov · Datasets · License: Public Domain · 2016

Open Source ↗

acute chronic drug-therapy leukemia myeloid

myelodysplastic syndromes, leukemia, myelomonocytic, chronic, leukemia, myeloid, acute, drug therapy, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Related documents